Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: A case control study

Human Immunology

Volumn 74, Issue 10, 2013, Pages 1368-1374

  Rafrafi, Ahlem ^a   Chahed, Besma ^a   Kaabachi, Safa ^a   Kaabachi, Wajih ^a   Maalmi, Haifa ^a   Hamzaoui, Kamel ^a   Sassi, Fayçal Haj ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

CI; COPD; IL 8; MRNA; NSCLC; OR; PCR RFLP; RT PCR; SNP; TS; X2

Indexed keywords

INTERLEUKIN 8;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; TUNISIA;

CHI(2) TEST; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CI; CONFIDENCE INTERVALS; COPD; IL-8; INTERLEUKIN-8; MESSENGER RIBONUCLEIC ACID; MRNA; NON SMALL CELL LUNG CANCER; NSCLC; ODDS RATIOS; OR; PCR-RFLP; POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION; RT-PCR; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; TOBACCO SMOKING (TS); TS; X(2);

ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR BURDEN; TUNISIA;

EID: 84883816037     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.06.033     Document Type: Article

References (53)

1. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-866.
2. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136(2):261-276.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
4. Toh C.K. The changing epidemiology of lung cancer. Methods Mol Biol 2009, 472:397-411.
5. Hecht S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002, 3:461-469.
6. Vlahos R., Bozinovski S., Jones J.E., Powell J., Gras J., Lilja A., et al. Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol 2006, 290:L931-L945.
7. Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008, 118:3546-3556.
8. Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat Rev Cancer 2003, 3:276-285.
9. Berns A. Cancer improved mouse models. Nature 2001, 410:1043-1044.
10. Tockman M.S., Anthonisen N.R., Wright E.C., Donithan M.G. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987, 106:512-518.
11. Ji H., Houghton A.M., Mariani T.J., Perera S., Kim C.B., Padera R., et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006, 25:2105-2112.
12. Karin M. Inflammation and cancer: the long reach of Ras. Nat Med 2005, 11:20-21.
13. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
14. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14:171-179.
15. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004, 14:181-185.
16. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2001, 2(2):95-101.
17. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology: XXII nomenclature for chemokine receptors. Pharmacol Rev 2000, 52(1):145-176.
18. Gangur V., Birmingham N.P., Thanesvorakul S. Chemokines in health and disease. Vet Immunol Immunopathol 2002, 86(3-4):127-136.
19. Strieter R.M., Belperio J.A., Burdick M.D., et al. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci 2004, 1028:351-360.
20. Arenberg D.A., Keane M.P., DiGiovine B., et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in nonsmall cell lung cancer. J Clin Invest 1998, 102:465-472.
21. White E.S., Flaherty K.R., Carskadon S., et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003, 9:853-860.
22. Matsushima K. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989, 1:2-13.
23. Matsushima K., Baldwin E.T., Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment and activity cytokines. Chem Immunol 1992, 51:236-265.
24. Masuya D., Huang C., Liu D., Kameyama K., Hayashi E., Yamauchi A., et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in non small cell lung carcinoma patients. Cancer 2001, 92:2628-2638.
25. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996, 97:2792-2802.
26. Yuan A., Yang P.C., Yu C.J., Chen W.J., Lin F.Y., Kuo S.H., et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small cell lung cancer. Am J Respir Crit Care Med 2000, 162:1957-1963.
27. Singh R.K., Gutman M., Radinsky R., Bucana C.D., Fidler I.J. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994, 54:3242-3247.
28. Mukaida N., Shiroo M., Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989, 143:1366-1371.
29. Mout R., Willemze R., Landegent J.E. Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res 1991, 19(13):3763.
30. Rosenwasser L.J., Klemm D.J., Dresback J.K., Inamura H., Mascali J.J., Klinnert M., et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995, 25(Suppl. 2):74-78. discussion 95-6.
31. Hull J., Thomson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000, 55:1023-1027.
32. Taguchi A., Ohmiya N., Shirai K., et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005, 14:2487-2493.
33. Hacking D., Knight J.C., Rockett K., Brown H., Frampton J., Kwiatkowski D.P., et al. Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun 2004, 5(4):274-282.
34. Song B, Zhang D, Wang S, Zheng H, Wang X. Association of interleukin-8 with cachexia from patients with low-third gastric cancer. Comparative and Functional Genomics. 2009;Article ID212345:6pp.
35. Hull J., Ackerman H., Isles K., et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet 2001, 69:413-419.
36. Lee W.P., Tai D.I., Lan K.H., et al. The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res 2005, 11:6431-6441.
37. Hamzaoui K., Bouali E., Ghorbel I., Khanfir M., Houman H., Hamzaoui A. Expression of Th-17 and RORγt mRNA in behçet's disease. Med Sci Monit 2011, 17(4):CR227-CR234.
38. Heinzmann A., Ahlert I., Kurz T., Berner R., Deichmann K.A. Association study suggests opposite effects of polymorphisms within IL8 on bronchial asthma and respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2004, 114(3):671-676.
39. Zhu Y.M., Webster S.J., Flower D., Woll P.J. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 2004, 91:1970-1976.
40. McCarron S.L., Edwards S., Evans P.R., Gibbs R., Dearnaley D.P., Dowe A., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002, 62:3369.
41. Landi S., Moreno V., Gioia-Patricola L., Guino E., Navarro M., de Oca J., et al. Association of common polymorphisms in inflammatory genes interleukin IL6, IL8, tumor necrosis factor, NFKB1, and peroxisome proliferator-activated receptor-with colorectal cancer. Cancer Res 2003, 63:3560.
42. Vairaktaris E., Yapijakis C., Serefoglou Z., Derka S., Vassiliou S., Nkenke E., et al. The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 2007, 33:504.
43. Ben Nasr H., Chahed K., Mestiri S., Bouaouina N., Snoussi K., Chouchane L. Association of IL-8 (-251) T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Hum Immunol 2007, 68:761-769.
44. Smith K.C., Baterman A.C., Fusselt H.M., Howell W.M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004, 31:167.
45. Snoussi K., Mahfoudh W., Bouaouina N., Fekih M., Khairi H., Helal A.N., et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 2010, 10:283.
46. Reyes-Gibby C.C., Shete S., Yennurajalingam S., Frazier M., Bruera E., Kurzrock R., et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage 2009, 38:894-902.
47. Reyes-Gibby C.C., Spitz M., Wu X., Merriman K., Etzel C., Bruera E., et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-a-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev 2007, 16(12):2745-2751.
48. Xue H., Liu J., Lin B., Wang Z., Sun J., Huang G. A meta-analysis of interleukin-8 -251 promoter polymorphism associated with gastric cancer risk. PloS One 2012, 7(1):e28083.
49. Campa D., Zienolddiny S., Maggini V., Skaug V., Aage Haugen A., Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004, 25(2):229-235.
50. Gao L.-B., Pan X.-M., Jia J., Liang W.-B., Rao L., Xue H., et al. IL-8 -251A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. Eur J Cancer 2010, 46:1333-1343.
51. Campa D., Hung R.J., Mates D., Zaridze D., Szeszenia-Dabrowska N., Rudnai P., et al. Lack of association between 251 T>A polymorphism of IL8 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2005, 14(10):2457-2458.
52. Wang N., Zhou R., Wang C.H., Guo X., Chen Z., Yang S., et al. 251 T/A polymorphism of the interleukin-8 gene and cancer risk: a huge review and meta-analysis based on 42 case-control studies. Mol Biol Rep 2012, 39:2831-2841.
53. Kamangar F., Abnet C.C., Hutchinson A.A., Newschaffer C.J., Helzlsouer K., Shugart Y.Y., et al. Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control 2006, 17:117-125.